Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Departments

In reply: Submassive pulmonary embolism (December 2016)

Ali Ataya, MD, Jessica Cope, PharmD, Abbas Shahmohammadi, MD and Hassan Alnuaimat, MD
Cleveland Clinic Journal of Medicine February 2017, 84 (2) 94-95; DOI: https://doi.org/10.3949/ccjm.84c.02004
Ali Ataya
University of Florida, Gainesville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Cope
University of Florida, Gainesville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abbas Shahmohammadi
University of Florida, Gainesville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hassan Alnuaimat
University of Florida, Gainesville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

We thank Dr. Katyal for his thoughtful comments.

Dr. Katyal points out that the grade of recommendation for thrombolysis in patients with massive pulmonary embolism was upgraded from 2C to 2B in the 2016 American College of Chest Physicians (ACCP) guidelines1 compared with the 2012 guidelines2 that we cited. The upgrade in this recommendation was owing to 2 small trials and 1 large randomized controlled trial that included patients with submassive pulmonary embolism.3–5 Interestingly, these 3 studies led to an upgrade in the level of recommendation for thrombolysis in the treatment of massive pulmonary embolism, perhaps more from a safety aspect (in view of the incidence of major bleeding vs mortality). Regardless, Dr. Katyal is correct in highlighting that the new 2016 ACCP guidelines now give a grade of 2B for thrombolytic therapy in the treatment of massive pulmonary embolism. These guidelines had not been published at the time of submission of our manuscript.

Dr. Katyal is also correct that patients were not required to have right ventricular dysfunction to be enrolled in the MOPETT trial.3 As we pointed out, “Only 20% of the participants were enrolled on the basis of right ventricular dysfunction on echocardiography, whereas almost 60% had elevated cardiac biomarkers.”6

Regarding catheter-directed therapy, patients who received low-dose catheter-directed alteplase were also concurrently anticoagulated with systemic unfractionated heparin in the Ultrasound-Assisted, Catheter-Directed Th rombolysis for Acute Intermediate-Risk Pulmonary Embolism (ULTIMA) trial.7 Th e ULTIMA trial authors commented that unfractionated heparin was started with an 80-U/kg bolus followed by an 18-U/kg/hour infusion to target an anti-factor Xa level of 0.3 to 0.7 μg/mL, which is considered therapeutic anticoagulation. Th e investigators in the SEATTLE II trial8 continued systemic unfractionated heparin but targeted a lower “intermediate” anticoagulation target (an augmented partial thromboplastin time of 40–60 seconds), so these patients weren’t completely without systemic anticoagulation either. At our institution, the current practice is to target an anti-Xa level of 0.3 to 0.7 μg/mL in patients receiving catheter-directed therapy for large-volume pulmonary embolism.

  • Copyright © 2017 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Kearon C,
    2. Akl EA,
    3. Ornelas J,
    4. et al
    . Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149:315–352.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kearon C,
    2. Akl EA,
    3. Comerota AJ,
    4. et al
    5. American College of Chest Physicians
    . Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(suppl 2):e419S–e494S.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Sharifi M,
    2. Bay C,
    3. Skrocki L,
    4. Rahimi F,
    5. Mehdipour M,
    6. “MOPETT” Investigators
    . Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 2013; 111:273–277.
    OpenUrlCrossRefPubMed
    1. Meyer G,
    2. Vicaut E,
    3. Danays T,
    4. et al
    5. PEITHO Investigators
    . Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370:1402–1411.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kline JA,
    2. Nordenholz KE,
    3. Courtney DM,
    4. et al
    . Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 2014; 12:459–468.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ataya A,
    2. Cope J,
    3. Shahmohammadi A,
    4. Alnuaimat H
    . Do patients with submassive pulmonary embolism benefit from thrombolytic therapy? Cleve Clin J Med 2016; 83:923–932.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kucher N,
    2. Boekstegers P,
    3. Muller OJ,
    4. et al
    . Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129:479–486.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Piazza G,
    2. Hohlfelder B,
    3. Jaff MR,
    4. et al
    5. SEATTLE II Investigators
    . A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism (The SEATTLE II Study). JACC Cardiovasc Interv 2015; 8:1382–1392.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 84 (2)
Cleveland Clinic Journal of Medicine
Vol. 84, Issue 2
1 Feb 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In reply: Submassive pulmonary embolism (December 2016)
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In reply: Submassive pulmonary embolism (December 2016)
Ali Ataya, Jessica Cope, Abbas Shahmohammadi, Hassan Alnuaimat
Cleveland Clinic Journal of Medicine Feb 2017, 84 (2) 94-95; DOI: 10.3949/ccjm.84c.02004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In reply: Submassive pulmonary embolism (December 2016)
Ali Ataya, Jessica Cope, Abbas Shahmohammadi, Hassan Alnuaimat
Cleveland Clinic Journal of Medicine Feb 2017, 84 (2) 94-95; DOI: 10.3949/ccjm.84c.02004
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Departments

  • Extraosseous calcification in kidney disease
  • Does my hospitalized patient need an NPO-after-midnight order preoperatively?
  • Our Peer-Reviewers For 2021
Show more Departments

Letters to the editor

  • Antiobesity drug therapy
  • Physician resistance to obesity pharmacotherapy
  • In Reply: Antiobesity drug therapy
Show more Letters to the editor

Similar Articles

Subjects

  • Pulmonology
  • Vascular Medicine
  • Hospital Medicine
  • Emergency Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2022 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire